ANTIBODIES AGAINST CITRULLINATED PROTEINS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: RELEVANCE OF LIKELIHOOD RATIOS

Background: Antibodies against citrullinated proteins (ACPA) and rheumatoid factor (RF) are part of the classification criteria for the diagnosis of rheumatoid arthritis (RA) and are useful in the diagnosis and prognosis of RA. Objective: To measure serum ACPA and RF levels in patients with early RA (up to 12 months)—including very early RA (<3 months)—who had not received treatment with disease-modifying antirheumatic drugs. Ninety patients with other autoimmune rheumatic diseases served as controls. Materials and Methods: There were 269 patients (226 women and 43 men) with a median age of 50 years seen at our hospital between 2012 and 2022. ACPA levels were measured using chemiluminescence (cut-off >17 U/mL) and RF levels were primarily measured using latex agglutination tests (cut-off ≥160). Sensitivity, specificity, likelihood ratios (LRs) and CI95% were calculated. Results: 215 (80%) patients tested positive for ACPA; specificity was 93% and the positive LR was 11.9 (excellent clinical utility). The sensitivity of the ACPA+RF combination was 43%, with 93% specificity and an LR of 6.3 (good clinical utility). RF sensitivity and specificity were 62% and 67%, respectively, with a positive LR of 1.8 (poor clinical utility). Among the 90 controls, 6 (7%) tested positive for both ACPA and RF ("rupus"), and 33 tested positive for RF. Conclusion: ACPA levels in early RA demonstrated high sensitivity, specificity, and LR >10. The combination of ACPA and RF offers good clinical utility compared to testing for RF alone.

• Aletha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. (2010). 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum, 62: 2569-8162:2569–2581. doi: 10.1002/art.27584.
• Berglin E, Padyukob L, Sundin U, Hallmans G, Stend L, van der Venrooij WJ et al. (2004) A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther., 11: R303-R308. DOI 10.1186/ar1187).
• Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. (2003). Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC Class II molecule. J Immunol, 171: 538-41. DOI: 10.4049/jimmunol.171.2.538.
• Cunningham KY, Hur B, Gupta VK, Arment CA, Wright KA, Mason TG et al. (2023) Patients with ACPA-positive and ACPA negative rheumatoid arthritis show different serological autoantibody repertoires and autoantibody associations with express disease activity. Scientific Reports, 13: 5360.https://doi.org/10.1038/s41598-023-32428-4
• Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT. (1985). When does rheumatoid disease start? Arthritis Rheum., 28: 485-489.doi: 10.1002/art.1780280503.
• Nielen MM, van Schaerdenburg D, Reesnik HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al. (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurement in the blood donors. Arthritis Rheum, 50: 380-386 https://doi.org/10.1002/art.20018
• Schellekens GA, de Long BA, van den Hoogen FH, van den Putte LB et al. (1988)    Citrulline is an essential constituent of antigenic determinants recognzed by rheumatoid arthritis-specific autoantibodies. J Clin Invest., 101: 273-8.doi: 10.1172/JCI1316.
• Schellekens GA, Visser H, de Long BA, van den Hoogen FH, Hazes JM, Breedveld FC et al. (2000). The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum., 43: 155-63. https://doi.org/10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3
• Deeks JJ, Altman DG. (2004). Diagnostic tests 4: likelihood ratios. BMJ., 329: 168-169. doi:10.1136/bmj.329.7458.168
• Ranganathan P, Aggarwal R. (2018) Understanding the properties of diagnostic test- Part 2: Likelihood ratios. Perspect Clin Res., 9(2): 99-102. doi:10.4103/picr. PICr 41 18.
• Firestein GS. (2005). Pathogenesis of rheumatoid arthritis:how early is early. Arthritis Res Ther., 7: 157-159. doi: 10.1038/nature01661.
• Nishimura K, Sugiyama D, Kogata Y, Tsugi G, Nakasawa T, Saigo K et al. 2007). Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med., 146: 787-808. doi: 10.7326/0003-4819-146-11-200706050-00008.
• González Arboleda ML, Rueda Gutiérrez J, González Buriticá H, Mercedes Salcedo Cifuentes M. Utilidad diagnóstica del anticuerpo antipéptido cíclico citrulinado como prueba diagnóstica en pacientes con artritis reumatoide. Rev Colomb Reumatol, 2013; 20: 9-18. DOI:10.1016/S0121-8123(13)70008-2